Quantcast

Industry news that matters to you.  Learn more

COLTHERES Consortium Identifies Molecular Signatures Leading to Personalized Therapies

COLTHERES (the Colon Therapy Research Consortium), a collaboration of EU-based clinical centers and translational researchers, has revealed in its first interim report key results that will enable a more personalized and effective approach to be taken in treatment of colon cancer using two novel drugs; the EGFR inhibitor Cetuximab and the BRaf inhibitor Vemurafinib.

High Levels of Blood-Based Protein Specific to Mesothelioma

Researchers at NYU School of Medicine have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease and patient prognosis.

Biomarker for Huntington’s Disease Identified

Huntington’s disease, a devastating genetic disorder that causes degeneration of nerve cells in the brain, affects more than 15,000 Americans, and at least 150,000 are at risk of developing the disease. There is no known cure or treatment for the disease — which starts with changes in mood, judgment, memory, and other cognitive functions and inevitably leads to increasing physical disability, dementia and death. In a new research paper published in the Proceedings of the National Academy of Sciences Early Edition online, researchers identify a transcriptional biomarker that may assist in the monitoring of disease activity and in the evaluation of new medications.

Over-expression of Repetitive, Non-protein Coding DNA Common in Tumor Cells

Researchers at Massachusetts General Hospital (MGH) Cancer Center have discovered massive over-expression of certain non-protein coding DNA sequences in common tumor cells. The DNA sequences, called satellite repeats, have not been previously thought to have a role in cancer. The study appears in the journal Science (link below).